bleomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	4742	11056-06-7

Description:

Molecule	Description
Synonyms: bleomycin bleomycins bleomycin sulfate bleomycin hydrochloride bleomycin HCl	A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Molecular weight: 2841.07 Formula: C110H168N37O42S5 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 688.97 ALOGS: ROTB: None

Molecule

Description

Synonyms:

bleomycin
bleomycins
bleomycin sulfate
bleomycin hydrochloride
bleomycin HCl

A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.

Molecular weight: 2841.07
Formula: C110H168N37O42S5
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 688.97
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.43 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.26 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 31, 1973	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	267	25.39	164	6547	97503	50500910
Pulmonary toxicity	200.52	25.39	59	6652	5503	50592910
Neutropenia	192.64	25.39	158	6553	147807	50450606
Ovarian germ cell teratoma	146.62	25.39	22	6689	56	50598357
Teratoma	127.16	25.39	21	6690	116	50598297
Second primary malignancy	115.85	25.39	41	6670	6873	50591540
Acute myeloid leukaemia	91.07	25.39	43	6668	15031	50583382
Deafness	86.41	25.39	42	6669	15649	50582764
Mucosal inflammation	86.05	25.39	58	6653	40084	50558329
Teratoma benign	80.66	25.39	13	6698	60	50598353
Myelodysplastic syndrome	78.82	25.39	39	6672	15093	50583320
Product use in unapproved indication	74.44	25.39	84	6627	115735	50482678
Hepatitis B reactivation	70.22	25.39	21	6690	2066	50596347
Bone marrow failure	69.16	25.39	44	6667	27580	50570833
Interstitial lung disease	65.20	25.39	55	6656	53121	50545292
Pulmonary fibrosis	63.87	25.39	40	6671	24397	50574016
Cutaneous calcification	63.17	25.39	11	6700	87	50598326
Febrile bone marrow aplasia	60.80	25.39	25	6686	6286	50592127
Chloroma	60.77	25.39	12	6699	199	50598214
Respiratory symptom	58.93	25.39	19	6692	2395	50596018
Pancytopenia	55.75	25.39	62	6649	83968	50514445
Tissue infiltration	54.40	25.39	13	6698	540	50597873
Premature baby	52.97	25.39	32	6679	18305	50580108
Basal ganglion degeneration	52.89	25.39	12	6699	396	50598017
Necrotising gastritis	52.17	25.39	9	6702	67	50598346
Drug resistance	51.93	25.39	32	6679	18957	50579456
Acute respiratory distress syndrome	51.30	25.39	33	6678	21066	50577347
Respiratory failure	48.37	25.39	60	6651	91121	50507292
Lung disorder	46.18	25.39	42	6669	44757	50553656
Uterine enlargement	45.93	25.39	13	6698	1053	50597360
Thrombocytopenia	45.08	25.39	69	6642	127604	50470809
Exposure during pregnancy	43.56	25.39	66	6645	120949	50477464
Foetal exposure during pregnancy	43.55	25.39	33	6678	27326	50571087
Peripheral sensory neuropathy	43.51	25.39	20	6691	6571	50591842
Aplasia	43.28	25.39	17	6694	3796	50594617
Combined immunodeficiency	42.19	25.39	8	6703	106	50598307
Sarcoidosis	42.05	25.39	18	6693	4999	50593414
Primary immunodeficiency syndrome	41.74	25.39	7	6704	43	50598370
Disease progression	41.38	25.39	57	6654	95809	50502604
Premature menopause	40.31	25.39	11	6700	779	50597634
Inguinal hernia	39.90	25.39	13	6698	1693	50596720
Malignant neoplasm progression	39.65	25.39	47	6664	68077	50530336
Hyperpyrexia	39.62	25.39	15	6696	3034	50595379
Flagellate dermatitis	38.50	25.39	8	6703	173	50598240
Vulvovaginal inflammation	38.39	25.39	10	6701	592	50597821
Anaesthesia	38.21	25.39	9	6702	351	50598062
Anaemia	37.84	25.39	95	6616	252361	50346052
Leukaemia	37.62	25.39	15	6696	3484	50594929
Acute hepatic failure	36.82	25.39	24	6687	15653	50582760
Psychogenic seizure	36.76	25.39	12	6699	1573	50596840
Cardiotoxicity	36.25	25.39	18	6693	7009	50591404
Septic shock	35.86	25.39	41	6670	57134	50541279
Haemophagocytic lymphohistiocytosis	35.54	25.39	19	6692	8614	50589799
Tumour lysis syndrome	35.32	25.39	18	6693	7403	50591010
Dysaesthesia	33.29	25.39	14	6697	3721	50594692
Transdifferentiation of neoplasm	33.24	25.39	5	6706	13	50598400
Encephalitis viral	32.67	25.39	11	6700	1586	50596827
Neurological decompensation	32.54	25.39	12	6699	2258	50596155
Lymphopenia	32.08	25.39	22	6689	15599	50582814
Hypochromic anaemia	32.02	25.39	11	6700	1685	50596728
Pleuroparenchymal fibroelastosis	32.02	25.39	5	6706	18	50598395
Capillary leak syndrome	30.86	25.39	11	6700	1879	50596534
Acute promyelocytic leukaemia	30.19	25.39	9	6702	875	50597538
Monoplegia	30.16	25.39	12	6699	2771	50595642
Myelosuppression	30.06	25.39	20	6691	13497	50584916
Traumatic lung injury	29.77	25.39	10	6701	1431	50596982
Abdominal compartment syndrome	29.72	25.39	8	6703	538	50597875
Off label use	29.09	25.39	132	6579	474294	50124119
Rash	28.89	25.39	11	6700	437460	50160953
Pain	28.78	25.39	21	6690	578882	50019531
Meningitis streptococcal	28.12	25.39	6	6705	148	50598265
Acute lymphocytic leukaemia	25.46	25.39	10	6701	2231	50596182

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	403.46	22.85	307	8759	111933	29453528
Second primary malignancy	318.57	22.85	107	8959	6598	29558863
Pulmonary toxicity	236.04	22.85	79	8987	4811	29560650
Acute myeloid leukaemia	225.10	22.85	107	8959	16406	29549055
Azoospermia	140.30	22.85	31	9035	374	29565087
Pulmonary fibrosis	128.36	22.85	72	8994	15510	29549951
Pneumonitis	118.68	22.85	85	8981	27959	29537502
Myelodysplastic syndrome	114.33	22.85	70	8996	17724	29547737
Interstitial lung disease	112.86	22.85	112	8954	57606	29507855
Neutropenia	104.28	22.85	162	8904	131549	29433912
Acute respiratory distress syndrome	86.78	22.85	65	9001	22870	29542591
Cardiotoxicity	74.68	22.85	34	9032	4710	29560751
Flagellate dermatitis	73.33	22.85	12	9054	20	29565441
Bone marrow failure	72.41	22.85	63	9003	27386	29538075
Traumatic lung injury	68.76	22.85	22	9044	1158	29564303
Endocarditis noninfective	68.33	22.85	14	9052	114	29565347
Papillary thyroid cancer	60.66	22.85	17	9049	565	29564896
Pneumomediastinum	60.19	22.85	22	9044	1734	29563727
Pyrexia	57.76	22.85	206	8860	287416	29278045
Chronic myeloid leukaemia	53.91	22.85	21	9045	1973	29563488
Respiratory failure	53.66	22.85	102	8964	97029	29468432
Pneumocystis jirovecii pneumonia	53.53	22.85	43	9023	16736	29548725
Cytomegalovirus chorioretinitis	53.47	22.85	24	9042	3214	29562247
Testicular disorder	51.41	22.85	15	9051	577	29564884
Vena cava thrombosis	51.29	22.85	17	9049	1001	29564460
Lung disorder	48.61	22.85	53	9013	30309	29535152
Thrombocytopenia	47.45	22.85	118	8948	134705	29430756
Coronary artery thrombosis	46.83	22.85	19	9047	1986	29563475
Scleroderma	46.74	22.85	17	9049	1321	29564140
Off label use	46.15	22.85	198	8868	300602	29264859
Pneumothorax	45.10	22.85	38	9028	15804	29549657
Osteonecrosis	43.87	22.85	35	9031	13484	29551977
Myositis	43.06	22.85	31	9035	10252	29555209
Product use in unapproved indication	42.83	22.85	87	8979	86788	29478673
Leukopenia	42.26	22.85	67	8999	55136	29510325
Chloroma	40.82	22.85	12	9054	474	29564987
Teratoma	39.94	22.85	7	9059	21	29565440
Subcutaneous emphysema	39.93	22.85	14	9052	978	29564483
Pulmonary embolism	39.33	22.85	78	8988	76456	29489005
Deafness	39.13	22.85	29	9037	10026	29555435
Malignant neoplasm progression	38.83	22.85	76	8990	73783	29491678
Autoimmune neutropenia	37.85	22.85	10	9056	265	29565196
Blood pressure decreased	37.31	22.85	57	9009	45420	29520041
Pancytopenia	37.14	22.85	80	8986	83088	29482373
Haematotoxicity	37.08	22.85	24	9042	6675	29558786
Mucosal inflammation	37	22.85	47	9019	31548	29533913
Taeniasis	34.73	22.85	7	9059	52	29565409
Acute myocardial infarction	33.28	22.85	56	9010	48382	29517079
Premature ageing	32.02	22.85	7	9059	80	29565381
Carotid artery thrombosis	31.16	22.85	9	9057	334	29565127
Neutropenic sepsis	31.07	22.85	27	9039	11700	29553761
Lung infiltration	30.96	22.85	27	9039	11752	29553709
Cerebral infarction	30.95	22.85	38	9028	24637	29540824
Osteosarcoma	30.92	22.85	8	9058	195	29565266
Ichthyosis	30.78	22.85	7	9059	97	29565364
Vascular access site occlusion	29.72	22.85	6	9060	45	29565416
Testicular malignant teratoma	29.64	22.85	5	9061	11	29565450
Pneumonia salmonella	29.27	22.85	6	9060	49	29565412
Fall	29.25	22.85	9	9057	177169	29388292
Dizziness	28.95	22.85	11	9055	189673	29375788
Septic shock	28.86	22.85	61	9005	62499	29502962
Vocal cord inflammation	28.65	22.85	6	9060	55	29565406
Cardiac dysfunction	28.59	22.85	13	9053	1794	29563667
Splenic infarction	28.37	22.85	13	9053	1826	29563635
Therapy partial responder	27.25	22.85	18	9048	5181	29560280
Rash	25.82	22.85	13	9053	189806	29375655
Cerebral venous thrombosis	25.66	22.85	9	9057	629	29564832
Organising pneumonia	25.30	22.85	17	9049	5031	29560430
Paternal exposure timing unspecified	25.19	22.85	5	9061	34	29565427
Ischaemic cerebral infarction	25.11	22.85	10	9056	995	29564466
Arterial thrombosis	24.91	22.85	11	9055	1417	29564044
Acute promyelocytic leukaemia	24.52	22.85	8	9058	448	29565013
Sarcoidosis	23.91	22.85	13	9053	2627	29562834
Spindle cell sarcoma	23.90	22.85	6	9060	129	29565332
Death	23.75	22.85	43	9023	342041	29223420
Cerebral artery stenosis	23.51	22.85	7	9059	289	29565172
Subdural haemorrhage	23.05	22.85	13	9053	2822	29562639
Pain	22.92	22.85	12	9054	171420	29394041

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	658.74	20.73	446	13875	187211	64297200
Second primary malignancy	414.15	20.73	140	14181	12197	64472214
Pulmonary toxicity	371.52	20.73	118	14203	8443	64475968
Acute myeloid leukaemia	340.45	20.73	151	14170	27312	64457099
Neutropenia	258.66	20.73	291	14030	239333	64245078
Myelodysplastic syndrome	197.01	20.73	104	14217	27475	64456936
Interstitial lung disease	176.04	20.73	157	14164	97575	64386836
Pulmonary fibrosis	172.82	20.73	98	14223	29780	64454631
Teratoma	147.05	20.73	26	14295	125	64484286
Ovarian germ cell teratoma	135.27	20.73	22	14299	56	64484355
Acute respiratory distress syndrome	134.45	20.73	92	14229	38843	64445568
Pneumonitis	128.35	20.73	99	14222	50266	64434145
Bone marrow failure	121.62	20.73	94	14227	47858	64436553
Pancytopenia	101.14	20.73	141	14180	143168	64341243
Thrombocytopenia	100.68	20.73	179	14142	223622	64260789
Flagellate dermatitis	100.36	20.73	20	14301	200	64484211
Mucosal inflammation	99.82	20.73	94	14227	62490	64421921
Teratoma benign	99.50	20.73	17	14304	64	64484347
Respiratory failure	96.91	20.73	147	14174	161036	64323375
Malignant neoplasm progression	96.48	20.73	122	14199	112749	64371662
Lung disorder	92.68	20.73	89	14232	60611	64423800
Pneumocystis jirovecii pneumonia	92.32	20.73	64	14257	27570	64456841
Product use in unapproved indication	90.88	20.73	150	14171	176468	64307943
Peripheral sensory neuropathy	87.19	20.73	45	14276	11333	64473078
Chloroma	86.98	20.73	22	14299	683	64483728
Traumatic lung injury	84.94	20.73	28	14293	2248	64482163
Pneumomediastinum	78.30	20.73	28	14293	2872	64481539
Chronic myeloid leukaemia	74.16	20.73	28	14293	3346	64481065
Pyrexia	71.23	20.73	278	14043	558366	63926045
Cardiotoxicity	71.22	20.73	38	14283	10236	64474175
Haematotoxicity	71.04	20.73	41	14280	12855	64471556
Endocarditis noninfective	66.46	20.73	14	14307	188	64484223
Sarcoidosis	64.10	20.73	30	14291	6116	64478295
Off label use	62.18	20.73	291	14030	632515	63851896
Myelitis	55.52	20.73	20	14301	2094	64482317
Cutaneous calcification	55.47	20.73	11	14310	107	64484304
Disease progression	54.42	20.73	106	14215	141574	64342837
Pain	53.80	20.73	28	14293	553483	63930928
Pneumothorax	53.79	20.73	44	14277	24254	64460157
Necrotising gastritis	52.87	20.73	10	14311	74	64484337
Acute promyelocytic leukaemia	51.49	20.73	17	14304	1371	64483040
Rash	49.50	20.73	20	14301	458529	64025882
Subcutaneous emphysema	49.03	20.73	17	14304	1592	64482819
Osteonecrosis	48.06	20.73	44	14277	28185	64456226
Septic shock	46.86	20.73	84	14237	105353	64379058
Papillary thyroid cancer	46.66	20.73	18	14303	2280	64482131
Deafness	46.53	20.73	36	14285	18323	64466088
Coronary artery thrombosis	46.16	20.73	19	14302	2850	64481561
Stem cell transplant	45.85	20.73	20	14301	3461	64480950
Febrile bone marrow aplasia	44.61	20.73	29	14292	11226	64473185
Leukopenia	44.15	20.73	80	14241	101162	64383249
Cytomegalovirus chorioretinitis	42.22	20.73	21	14300	4891	64479520
Therapy partial responder	42.09	20.73	27	14294	10221	64474190
Haemophagocytic lymphohistiocytosis	41.33	20.73	33	14288	17576	64466835
Tumour lysis syndrome	40.52	20.73	34	14287	19406	64465005
Myositis	39.10	20.73	31	14290	16346	64468065
Acute lymphocytic leukaemia	38.50	20.73	19	14302	4352	64480059
Myelosuppression	38.35	20.73	36	14285	23794	64460617
Combined immunodeficiency	38.22	20.73	8	14313	104	64484307
Tissue infiltration	37.82	20.73	11	14310	582	64483829
Basal ganglion degeneration	37.13	20.73	10	14311	398	64484013
Taeniasis	36.98	20.73	7	14314	52	64484359
Autoimmune neutropenia	36.89	20.73	10	14311	408	64484003
Azoospermia	35.94	20.73	8	14313	141	64484270
Vulvovaginal inflammation	35.53	20.73	10	14311	470	64483941
Pleuroparenchymal fibroelastosis	35.46	20.73	6	14315	21	64484390
Primary immunodeficiency syndrome	35.40	20.73	7	14314	67	64484344
Fall	34.99	20.73	25	14296	416801	64067610
Vena cava thrombosis	34.94	20.73	15	14306	2497	64481914
Uterine enlargement	34.83	20.73	11	14310	770	64483641
Scleroderma	33.89	20.73	18	14303	4800	64479611
Premature ageing	33.80	20.73	7	14314	86	64484325
Leukaemia	32.97	20.73	18	14303	5070	64479341
Cerebral infarction	32.87	20.73	43	14278	41001	64443410
Aplasia	32.79	20.73	20	14301	6933	64477478
Lung infiltration	32.55	20.73	31	14290	20858	64463553
Cerebral venous thrombosis	32.07	20.73	14	14307	2427	64481984
Joint swelling	31.60	20.73	5	14316	215377	64269034
Acute myocardial infarction	31.54	20.73	56	14265	69662	64414749
Bacterial infection	31.46	20.73	33	14288	24917	64459494
Ichthyosis	31.31	20.73	7	14314	126	64484285
Testicular malignant teratoma	31.25	20.73	5	14316	11	64484400
Pneumonia salmonella	31.20	20.73	6	14315	49	64484362
Weight increased	31.19	20.73	5	14316	213343	64271068
Hepatitis B reactivation	30.86	20.73	17	14304	4872	64479539
Respiratory disorder	30.75	20.73	39	14282	36072	64448339
Organising pneumonia	30.29	20.73	21	14300	9034	64475377
Diarrhoea	30.24	20.73	73	14248	722631	63761780
Vascular access site occlusion	30.11	20.73	6	14315	60	64484351
Anaemia	29.20	20.73	163	14158	378517	64105894
Hodgkin's disease recurrent	28.83	20.73	5	14316	21	64484390
Peripheral sensorimotor neuropathy	28.14	20.73	13	14308	2572	64481839
Cytopenia	28.07	20.73	25	14296	15446	64468965
Blood pressure decreased	27.75	20.73	60	14261	86139	64398272
Anaesthesia	27.73	20.73	8	14313	411	64484000
Hyperpyrexia	27.58	20.73	16	14305	5061	64479350
Ototoxicity	27.50	20.73	13	14308	2710	64481701
Fatigue	27.26	20.73	81	14240	748649	63735762
Anxiety	26.96	20.73	6	14315	202643	64281768
Neoplasm progression	26.90	20.73	39	14282	40925	64443486
Pulmonary embolism	26.48	20.73	82	14239	146274	64338137
Left ventricular dysfunction	26.11	20.73	25	14296	16929	64467482
Encephalitis viral	26.01	20.73	12	14309	2368	64482043
B precursor type acute leukaemia	25.68	20.73	7	14314	292	64484119
Psychogenic seizure	25.63	20.73	11	14310	1830	64482581
Lymphopenia	25.56	20.73	30	14291	25627	64458784
Dizziness	25.50	20.73	35	14286	430128	64054283
Splenic infarction	25.29	20.73	13	14308	3244	64481167
Swelling	25.19	20.73	3	14318	160215	64324196
Death	25.05	20.73	43	14278	482662	64001749
Testicular cancer metastatic	24.49	20.73	5	14316	57	64484354
Hypothyroidism	24.39	20.73	37	14284	40420	64443991
Arthralgia	24.25	20.73	38	14283	442222	64042189
Nasopharyngitis	23.79	20.73	7	14314	196066	64288345
Blood pressure increased	23.17	20.73	5	14316	172547	64311864
Vocal cord inflammation	22.94	20.73	6	14315	213	64484198
Arterial thrombosis	22.71	20.73	11	14310	2419	64481992
Spindle cell sarcoma	22.68	20.73	6	14315	223	64484188
Carotid artery thrombosis	22.63	20.73	10	14311	1785	64482626
Sinusitis	22.29	20.73	3	14318	145925	64338486
Urinary tract infection	22.02	20.73	12	14309	231584	64252827
Oropharyngeal squamous cell carcinoma	21.99	20.73	6	14315	251	64484160
Transdifferentiation of neoplasm	21.91	20.73	5	14316	99	64484312
Venoocclusive liver disease	21.87	20.73	18	14303	9997	64474414
Monoplegia	21.81	20.73	12	14309	3431	64480980
Lymphadenopathy	21.76	20.73	38	14283	46648	64437763
Hodgkin's disease nodular sclerosis	21.73	20.73	4	14317	25	64484386
Abdominal compartment syndrome	21.43	20.73	9	14312	1419	64482992
Neuropathy peripheral	21.39	20.73	66	14255	117459	64366952
Ischaemic cerebral infarction	21.25	20.73	10	14311	2062	64482349
Abdominal discomfort	21.24	20.73	7	14314	182315	64302096
Pruritus	21.05	20.73	23	14298	312377	64172034
Drug resistance	21.01	20.73	32	14289	35070	64449341
Osteosarcoma	20.95	20.73	6	14315	300	64484111

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01DC01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Other cytotoxic antibiotics
CHEBI has role	CHEBI:25212	metabolites
CHEBI has role	CHEBI:35610	antineoplastic agents
MeSH PA	D000903	Antibiotics, Antineoplastic
MeSH PA	D000970	Antineoplastic Agents
FDA EPC	N0000180854	Cytoprotective Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diffuse non-Hodgkin's lymphoma, large cell	indication	109969005
Hodgkin's disease	indication	118599009
Non-Hodgkin's lymphoma	indication	118601006
Malignant tumor of head and/or neck	indication	255056009
Follicular non-Hodgkin's lymphoma	indication	308121000
Malignant tumor of cervix	indication	363354003	DOID:4362
Malignant tumor of penis	indication	363516004	DOID:11615
International Federation of Gynecology and Obstetrics stage finding for vulvar carcinoma	indication	385370007
Squamous cell carcinoma	indication	402815007	DOID:1749
Pleural Malignant Effusions	indication
Testicular Germ Cell Tumor	indication
Mycosis fungoides	off-label use	118618005
Ovarian Germ Cell Tumor Carcinoma	off-label use

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Aspartyl/asparaginyl beta-hydroxylase	Enzyme	Q12797	ASPH_HUMAN		IC50	5.83		CHEMBL

External reference:

ID	Source
D02177	KEGG_DRUG
4019637	VUID
N0000147730	NUI
9041-93-4	SECONDARY_CAS_RN
67763-87-5	SECONDARY_CAS_RN
4018135	VANDF
4019637	VANDF
CHEBI:3139	CHEBI
CHEMBL403664	ChEMBL_ID
CHEMBL3085504	ChEMBL_ID
2721	INN_ID
DB00290	DRUGBANK_ID
40S1VHN69B	UNII
5360373	PUBCHEM_CID
1621	RXNORM
4293	MMSL
9784	MMSL
d00177	MMSL
002661	NDDF
004820	NDDF
009872	NDDF
15660006	SNOMEDCT_US
372843005	SNOMEDCT_US
703085003	SNOMEDCT_US
76591000	SNOMEDCT_US
D001761	MESH_DESCRIPTOR_UI
C0005740	UMLSCUI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9240	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9240	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9241	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9241	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-0332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	21 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3154	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	19 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3155	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	19 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16714-886	POWDER, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	16714-908	POWDER, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	23 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-323	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	61703-332	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	13 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-136	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	12 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-137	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	12 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	69097-364	INJECTION	15 [USPU]	INTRAMUSCULAR	ANDA	20 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1567	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15000 [iU]	INTRA-ARTERIAL	UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE	18 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	71288-106	POWDER, FOR SOLUTION	15 [USPU]	INTRAMUSCULAR	ANDA	24 sections
Bleomycin	HUMAN PRESCRIPTION DRUG LABEL	1	71288-107	POWDER, FOR SOLUTION	30 [USPU]	INTRAMUSCULAR	ANDA	24 sections